MNPR | tickerfilter.com

Fundamental analysis

18%

Profitability 18%

Dept financing 1%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

11.04%

1 Month

-1.13%

3 Months

-24.62%

6 Months

38.89%

1 Year

106.12%

2 Year

6,954.86%

Key data

Stock price

$57.61

P/E Ratio

0.00

DAY RANGE

$53.50 - $57.87

EPS

-$1.33

52 WEEK RANGE

$26.06 - $105.00

52 WEEK CHANGE

$106.12

MARKET CAP

503.901 M

YIELD

N/A

SHARES OUTSTANDING

6.683 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.03

PUBLIC FLOAT

AVERAGE 10 VOLUME

$141,438

AVERAGE 30 VOLUME

$208,770

Company detail

CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

MNPR - Monopar Therapeutics